Cargando…
Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605506/ https://www.ncbi.nlm.nih.gov/pubmed/37894286 http://dx.doi.org/10.3390/cancers15204919 |
_version_ | 1785127090747604992 |
---|---|
author | Tonelli, Francesco Marini, Francesca Giusti, Francesca Iantomasi, Teresa Giudici, Francesco Brandi, Maria Luisa |
author_facet | Tonelli, Francesco Marini, Francesca Giusti, Francesca Iantomasi, Teresa Giudici, Francesco Brandi, Maria Luisa |
author_sort | Tonelli, Francesco |
collection | PubMed |
description | SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of a more conservative intervention, compared to both pancreaticoduodenectomy (PD) and distal pancreatectomy (DP), was associated with the absence of post-surgical complications, but required further pancreas surgeries for tumor relapse in 40.0% of the operated cases. Our data showed that major pancreatic resections (PD and DP) were effective in both preventing tumoral progression and guaranteeing a long-term PNEN relapse-free survival time in most of N+ and/or M+ patients. ABSTRACT: Pancreatic neuroendocrine neoplasms (PNENs) affect over 80% of patients with multiple endocrine neoplasia type 1 (MEN1). Surgery is usually the therapy of choice, but the real immediate and long-term therapeutic benefit of a partial extensive pancreatic resection remains controversial. We analyzed, in 43 PNEN MEN1 patients who underwent 19 pancreaticoduodenectomies (PD), 19 distal pancreatectomies (DP), and 5 minimal pancreatectomies, the prevalence of surgery-derived early complications and post-operative pancreatic sequelae, and the PNEN relapse-free survival time after surgery, comparing major (PD+DP) and minimal pancreatic surgeries. No post-operative mortality was observed. Metastatic cancers were found in 12 cases, prevalently from duodenal gastrinoma. Long-term cure of endocrine syndromes, by the 38 major pancreatic resections, was obtained in 78.9% of gastrinomas and 92.9% of insulinomas. In only one patient, hepatic metastases, due to gastrinoma, progressed to death. Out of the 38 major surgeries, only one patient was reoperated for the growth of a new PNEN in the remnant pancreas. No functioning PNEN persistence was reported in the five minimal pancreatic surgeries, PNEN relapse occurred in 60% of patients, and 40% of cases needed further pancreatic resection for tumor recurrence. No significant difference in PNEN relapse-free survival time after surgery was found between major and minimal pancreatic surgeries. |
format | Online Article Text |
id | pubmed-10605506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106055062023-10-28 Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries Tonelli, Francesco Marini, Francesca Giusti, Francesca Iantomasi, Teresa Giudici, Francesco Brandi, Maria Luisa Cancers (Basel) Article SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of a more conservative intervention, compared to both pancreaticoduodenectomy (PD) and distal pancreatectomy (DP), was associated with the absence of post-surgical complications, but required further pancreas surgeries for tumor relapse in 40.0% of the operated cases. Our data showed that major pancreatic resections (PD and DP) were effective in both preventing tumoral progression and guaranteeing a long-term PNEN relapse-free survival time in most of N+ and/or M+ patients. ABSTRACT: Pancreatic neuroendocrine neoplasms (PNENs) affect over 80% of patients with multiple endocrine neoplasia type 1 (MEN1). Surgery is usually the therapy of choice, but the real immediate and long-term therapeutic benefit of a partial extensive pancreatic resection remains controversial. We analyzed, in 43 PNEN MEN1 patients who underwent 19 pancreaticoduodenectomies (PD), 19 distal pancreatectomies (DP), and 5 minimal pancreatectomies, the prevalence of surgery-derived early complications and post-operative pancreatic sequelae, and the PNEN relapse-free survival time after surgery, comparing major (PD+DP) and minimal pancreatic surgeries. No post-operative mortality was observed. Metastatic cancers were found in 12 cases, prevalently from duodenal gastrinoma. Long-term cure of endocrine syndromes, by the 38 major pancreatic resections, was obtained in 78.9% of gastrinomas and 92.9% of insulinomas. In only one patient, hepatic metastases, due to gastrinoma, progressed to death. Out of the 38 major surgeries, only one patient was reoperated for the growth of a new PNEN in the remnant pancreas. No functioning PNEN persistence was reported in the five minimal pancreatic surgeries, PNEN relapse occurred in 60% of patients, and 40% of cases needed further pancreatic resection for tumor recurrence. No significant difference in PNEN relapse-free survival time after surgery was found between major and minimal pancreatic surgeries. MDPI 2023-10-10 /pmc/articles/PMC10605506/ /pubmed/37894286 http://dx.doi.org/10.3390/cancers15204919 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tonelli, Francesco Marini, Francesca Giusti, Francesca Iantomasi, Teresa Giudici, Francesco Brandi, Maria Luisa Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title | Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title_full | Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title_fullStr | Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title_full_unstemmed | Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title_short | Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries |
title_sort | pancreatic neuroendocrine tumors in men1 patients: difference in post-operative complications and tumor progression between major and minimal pancreatic surgeries |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605506/ https://www.ncbi.nlm.nih.gov/pubmed/37894286 http://dx.doi.org/10.3390/cancers15204919 |
work_keys_str_mv | AT tonellifrancesco pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries AT marinifrancesca pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries AT giustifrancesca pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries AT iantomasiteresa pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries AT giudicifrancesco pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries AT brandimarialuisa pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries |